News

Bill & Melinda Gates Foundation has awarded EPFL-based non-profit iM4TB $2.45 million for PBTZ169 clinical trials


11 May 2017
by Working Group

iM4TB is a non-profit based in EPFL’s Innovation Park. Founded in 2013, its mission is “to develop better and faster-acting medicines to fight TB and therefore bridge the gap between the scientific discovery and the market in order to provide affordable TB treatment to anyone in the world.” 

iM4TB is chaired by Professor Stewart Cole, a world-renowned TB expert, who also directs EPFL’s Global Health Institute. The non-profit enjoys the patronage of Professor Françoise Barré-Sinoussi, a French virologist who won the Nobel Prize in Medicine (2008) for the discovery of HIV, the virus that causes AIDS. 

iM4TB has developed a novel anti-TB drug called PBTZ169 (license held by EPFL). The antibiotic has now proven effective in pre-clinical trials, while previous in vivo studies have shown that it works faster and more effectively than anti-TB drugs currently recommended by the World Health Organization.

PBTZ169 works by preventing the TB bacterium, Mycobacterium tuberculosis, from building its waxy cell envelope, which protects the bacterium from attack by the patient’s immune system and antibiotics. By effectively destroying the envelope, PBTZ169 can kill drug-resistant TB bacteria, and potentially shorten therapy.

For full article click here

More News
4 May 2022
Earlier this week, the World Health Organization (WHO) released a rapid communication which detailed the upcoming changes to the treatment guidance for drug-resistant tuberculosis (DR-TB). These guidelines are used to inform national TB programmes globally on how to treat patients with these...
5 Apr 2022
On April 01, 2022, the Stop TB Partnership launched the second online consultation for the new Global Plan to End TB 2023-2030. Over the years, the Global Plans have been important tools for advocacy and resource mobilization, and served as a reference document for donors and stakeholders. In May...
23 Mar 2022
On March 21st, 2022, the World Health Organization (WHO) updated its guidelines on treatment of non-severe TB disease in children and adolescents. The new guidelines recommend a shorter duration of treatment and reduces the standard of care which is currently 6 months of therapy down to 4 months...